首页> 外文期刊>Stem cell research >MiR-17-5p and miR-106a are involved in the balance between osteogenic and adipogenic differentiation of adipose-derived mesenchymal stem cells
【24h】

MiR-17-5p and miR-106a are involved in the balance between osteogenic and adipogenic differentiation of adipose-derived mesenchymal stem cells

机译:MiR-17-5p和miR-106a参与脂肪间充质干细胞成骨和成脂分化之间的平衡

获取原文
获取原文并翻译 | 示例
           

摘要

Mesenchymal stem cells (MSCs) can differentiate into several distinct cell types, including osteoblasts and adipocytes. The balance between osteogenic and adipogenic differentiation is disrupted in several osteogenic-related disorders, such as osteoporosis. So far, little is known about the molecular mechanisms that drive final lineage commitment of MSCs. In this study, we revealed that miR-17-5p and miR-106a have dual functions in the modulation of human adipose-derived mesenchymal stem cells (hADSCs) commitment by gain- and loss-of-function assays. They could promote adipogenesis and inhibit osteogenesis. Luciferase reporter assay, western blot and ELISA suggested BMP2 was a direct target of miR-17-5p and miR-106a. Downregulation of endogeneous BMP2 by RNA interference suppressed osteogenesis and increased adipogenesis, similar to the effect of miR-17-5p and miR-106a upregulation. Moreover, the inhibitory effects of miR-17-5p on osteogenic and adipogenic differentiation of hADSCs could be reversed by BMP2 RNA interference. In conclusion, miR-17-5p and miR-106a regulate osteogenic and adipogenic lineage commitment of hADSCs by directly targeting BMP2, and subsequently decreased osteogenic TAZ, MSX2 and Runx2, and increased adipogenic C/EBPα and PPARγ.
机译:间充质干细胞(MSC)可以分化为几种不同的细胞类型,包括成骨细胞和脂肪细胞。成骨和成脂分化之间的平衡在一些成骨相关疾病(例如骨质疏松症)中被破坏。到目前为止,对驱动MSC最终谱系承诺的分子机制了解甚少。在这项研究中,我们揭示了miR-17-5p和miR-106a在通过功能获得和功能丧失测定来调节人脂肪来源的间充质干细胞(hADSCs)承诺中具有双重功能。它们可以促进脂肪生成并抑制成骨。萤光素酶报告基因测定,Western印迹和ELISA表明BMP2是miR-17-5p和miR-106a的直接靶标。 RNA干扰对内源性BMP2的下调抑制了成骨作用并增加了脂肪形成,类似于miR-17-5p和miR-106a上调的作用。此外,BMP2 RNA干扰可以逆转miR-17-5p对hADSCs成骨和成脂分化的抑制作用。总之,miR-17-5p和miR-106a通过直接靶向BMP2来调节hADSC的成骨和成脂谱系承诺,随后降低成骨TAZ,MSX2和Runx2,并增加成脂C /EBPα和PPARγ。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号